<DOC>
	<DOC>NCT00957437</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacokinetics of different extended-release formulations of AZD1305 when given as single and multiple oral doses to healthy male volunteers.</brief_summary>
	<brief_title>Study to Assess Drug Concentrations in Plasma of Different Extended-release Formulations of AZD1305</brief_title>
	<detailed_description />
	<criteria>Provision of signed, written and dated informed consent prior to any study specific procedures. Body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg. History or presence of any clinically significant disease or disorder in the opinion of the investigator. Use of nicotine in the last 4 weeks before screening and not more than 7 cigarettes per week (equivalent to 1 nicotine patch or 7 nicotine gums per week) before then. There will be no smoking until followup visit. Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs or ECG at baseline in the opinion of the investigator.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>male</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>AZD1305</keyword>
</DOC>